转移性去势抵抗性前列腺癌的基因组图谱的临床可操作性。
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer.
机构信息
Department of Urology, University Hospitals Leuven, 3000 Leuven, Belgium.
Laboratory of Molecular Endocrinology, KU Leuven, 3000 Leuven, Belgium.
出版信息
Cells. 2020 Nov 17;9(11):2494. doi: 10.3390/cells9112494.
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
靶向治疗的发展增加了转移性去势抵抗性前列腺癌（mCRPC）患者的治疗选择。需要有强大的预测和预后标志物来指导医生治疗 mCRPC 患者。在这篇综述中，我们揭示了 AR 通路、PI3K AKT 信号通路和 DNA 修复通路中可能的作用机制。此外，我们还就生物标志物试验设计和这类新型数据的临床应用提出了建议。
Zotero 插件